Table 1.
Baseline characteristics the study population*
| GB242 3 mg/kg (N = 283) |
INF 3 mg/kg (N = 283) |
Total (N = 566) | |
|---|---|---|---|
| Age (years) | |||
| Median (IQR) | 49 (18–72) | 49 (21–74) | 49 (18–74) |
| Gender, # (%) | |||
| Male | 42 (14.8) | 47 (16.6) | 89 (15.7) |
| Female | 241 (85.2) | 236 (83.4) | 477 (84.3) |
| BMI (kg/m2), median (IQR) | 22.670 (15.99–38.86) | 22.480 (15.22–33.91) | 22.505 (15.22–38.86) |
| Disease duration (years) | 6.691 (6.7319) | 5.813 (5.8444) | 6.253 (6.3143) |
| SJC median (IQR) | 9 (1–28) | 9 (0–28) | 9 (0–28) |
| TJC median (IQR) | 14 (2–28) | 13 (2–28) | 14 (2–28) |
| Patient’s assessment of pain, VAS (cm) | 7.03 (1.783) | 6.99 (1.650) | 7.01 (1.716) |
| Patient global assessment of disease activity VAS (cm) | 7.03 (1.797) | 7.01 (1.613) | 7.02 (1.706) |
| Physician global assessment of disease activity VAS (cm) | 6.867 (1.5362) | 6.849 (1.3855) | 6.858 (1.4615) |
| ESR (mm/h) | 51.1 (23.56) | 47.9 (23.18) | 49.5 (23.41) |
| CRP (mg/dl) | 3.3391 (5.6292) | 3.1331 (3.3707) | 3.2361 (4.6365) |
| Duration of prior MTX therapy (years) | 3.652 (3.7027) | 3.395 (3.9367) | 3.523 (3.8205) |
| History of glucocorticoids | 177(44.9%) | 133(47.0%) | 260(45.9%) |
BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, INF innovator infliximab, MTX methotrexate, SJC swollen joint count, TJC tender joint count
*Except where indicated otherwise, values are the mean (SD)